Listen to these podcast interviews on the iPad edition of this issue conducted by Peter Goodwin
Banked T-Cells Rescue Patients with Post-Transplant EBV-LPD
Donor T-cells brought long remissions to patients with rituximab-refractory or relapsing post-transplant Epstein Barr virus-associated lymphoproliferative disorder, which is otherwise lethal within just a few weeks. The study was reported at the meeting by Richard O'Reilly, MD, Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center, who discusses the results. Adding further commentary is study coauthor Susan Prockop, MD, Assistant Attending in the MSKCC's Pediatric Bone Marrow Transplantation Service (Abstract CT107, OT 6/25/15 issue).
Metastatic TNBC: Monoclonal Antibody Leads to Durable Remissions
Patients with triple-negative breast cancer treated with a monoclonal antibody to the PDL1 checkpoint inhibitor had durable remissions, with "acceptable" toxicity in a Phase I study that was featured in an ASCO news conference (Abstract 2859, OT 6/10/15 issue). Leisha Emens, MD, PhD, Associate Professor of Oncology and a member of the Cancer Immunology and Breast and Ovarian Cancer Programs at Johns Hopkins Kimmel Cancer Center in Baltimore, discusses the efficacy and safety findings. Added expert commententary is Louis M. Weiner, MD, Professor and Director of Lombardi Comprehensive Cancer Center of Georgetown University, who moderated the news conference.
If you are not yet receiving our iPad issues, download the free Oncology Times app from the App Store today! Visithttp://bit.ly/OT-iPadApp, search in the App Store, or follow the link onhttp://oncology-times.com.